8-K: Delcath Systems Reports Q1 2026 Results, Guides $100M+ Revenue

Delcath Systems announced first quarter 2026 financial results, with total revenue reaching $25.0 million, and provided full-year revenue guidance of at least $100 million.

Summary

• Delcath Systems reported first quarter 2026 revenue of $25.0 million, an increase from $19.8 million in the first quarter of 2025.
• HEPZATO KIT revenue was $23.3 million, up from $18.0 million in Q1 2025, while CHEMOSAT revenue was $1.7 million, down from $1.8 million.
• The company reported a net loss of $1.1 million for the quarter, compared to a net income of $1.1 million in Q1 2025.
• Non-GAAP adjusted EBITDA was $3.4 million, a decrease from $7.6 million in the prior year's quarter.
• Cash provided by operations was $0.9 million, down from $2.2 million in Q1 2025.
• Delcath repurchased approximately $3.0 million of its common stock under its share buyback program.
• The company ended the quarter with $89.3 million in cash and investments and no debt.
• Full-year 2026 revenue guidance is set at a minimum of $100 million, with an expected HEPZATO KIT volume increase of at least 20% over 2025.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed report. While revenue and future guidance are positive, the decline in profitability and adjusted EBITDA, alongside increased operating expenses, presents a concerning trend for the current quarter.

Positives

• Total revenue increased by 26.3% to $25.0 million in Q1 2026 compared to $19.8 million in Q1 2025.
• HEPZATO KIT revenue saw significant growth, increasing to $23.3 million from $18.0 million in the prior year's quarter.
• The company has a strong cash position of $89.3 million with no debt as of March 31, 2026.
• Full-year 2026 revenue guidance of at least $100 million indicates strong expected growth.
• The publication of CHOPIN trial results in The Lancet Oncology is expected to positively impact prescribing patterns.
• CHEMOSAT has been included as a recommended therapy in the ESMO EURACAN Clinical Practice Guideline for Uveal Melanoma.
• The company repurchased $3.0 million of its common stock, demonstrating a commitment to shareholder value.
• Positive adjusted EBITDA is projected for the full year 2026.

Negatives

• Net loss for the quarter was $1.1 million, a reversal from a net income of $1.1 million in Q1 2025.
• Non-GAAP adjusted EBITDA decreased significantly to $3.4 million from $7.6 million in Q1 2025.
• Cash provided by operations declined to $0.9 million from $2.2 million in the prior year's quarter.
• Gross margins slightly decreased to 85% from 86% in the prior year's quarter.
• Research and development expenses more than doubled to $9.8 million from $5.0 million in Q1 2025.
• Selling, general and administrative expenses increased to $13.1 million from $11.3 million in Q1 2025.

Risks

• The company faces uncertainties related to the successful commercialization of HEPZATO KIT.
• There are risks associated with securing an adequate supply of critical components for HEPZATO KIT manufacturing.
• Successful FDA inspections of the company's and its third-party suppliers' facilities are crucial.
• The implementation and management of the HEPZATO KIT Risk Evaluation and Mitigation Strategy (REMS) present challenges.
• Obtaining reimbursement for HEPZATO KIT is a potential risk.
• The company may face challenges in entering into necessary purchase and sale agreements with users of HEPZATO KIT.
• The company's ability to manage increased operating expenses, particularly in R&D and SG&A, while transitioning to profitability.

Future Outlook

The company projects full-year 2026 revenue to be at least $100 million, driven by an anticipated increase in HEPZATO KIT volume of at least 20% over 2025. Gross margins are expected to be in the range of 84% to 87%, and the company anticipates positive adjusted EBITDA for the full year.

Management Comments

• "We delivered a strong first quarter, marked by 20% volume growth over the prior quarter and a strong increase in new patient starts."
• "The recent publication of the full CHOPIN results in The Lancet Oncology is already having a meaningful impact on prescribing patterns, further validating HEPZATO KIT and positioning us for continued momentum and long-term value for patients and shareholders alike."

Industry Context

StockSavvy.ai notes that Delcath Systems operates in the highly specialized field of interventional oncology, focusing on liver-directed therapies. The company's performance is closely tied to the adoption and reimbursement of its proprietary technologies, HEPZATO KIT and CHEMOSAT, in treating complex liver cancers. The recent inclusion in clinical practice guidelines and publication in a leading oncology journal are positive indicators for market penetration.

Comparison to Industry Standards

• The reported Q1 2026 revenue of $25.0 million shows year-over-year growth, which is a positive sign in the competitive oncology market.
• The decrease in net income and adjusted EBITDA, despite revenue growth, suggests increasing operational costs or investment in growth, a common trend for companies in the clinical-stage or early commercialization phase of novel therapies.
• The company's focus on specialized treatments like percutaneous hepatic perfusion (PHP) positions it against other regional therapies and systemic treatments for liver cancers.

Stakeholder Impact

• Shareholders: The decline in profitability and adjusted EBITDA may be a concern, but the positive revenue growth and strong full-year guidance could be viewed favorably.
• Patients: Continued availability and potential expanded use of HEPZATO KIT and CHEMOSAT offer treatment options for liver cancer.
• Healthcare Providers: The inclusion of CHEMOSAT in clinical guidelines may increase its adoption and use.

Next Steps

• Continue commercialization efforts for HEPZATO KIT.
• Monitor the impact of the CHOPIN trial results publication on prescribing patterns.
• Execute on the 2026 full-year revenue guidance of at least $100 million.
• Manage increased R&D and SG&A expenses to drive future growth.

Key Dates

Recommendation

The company shows revenue growth and a strong future outlook with significant revenue guidance. However, the current quarter's results indicate a worsening profitability trend with a net loss and decreased adjusted EBITDA, alongside increased operating expenses. This mixed performance warrants a 'hold' recommendation pending further clarity on cost management and sustained profitability.

Keywords

Delcath Systems, HEPZATO KIT, CHEMOSAT, Interventional Oncology, Liver Cancer, Melphalan, Percutaneous Hepatic Perfusion, Financial Results